Solara Active Pharma Sciences Share Price

Solara Active

CMP as on 17-May-22 15:43

₹ 446.35
2.10 0.47%

Open

₹ 449.90

Turnover (lac)

₹ 347

Prev. Close

₹ 444.25

Day's Vol (shares)

₹ 77,729

Day's Range (₹)

₹ 421.10
₹ 451.05

CMP as on17-May-22 15:29

₹ 449.20
3.75 0.84%

Open

₹ 472.00

Turnover (lac)

₹ 72

Prev. Close

₹ 445.45

Day's Vol (shares)

₹ 31,102

Day's Range

₹ 400.95
₹ 472.00

Corporate Action

Go
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 22-Apr-2022 - -
Audited Results Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/04/2022 ,inter alia, to consider and approve This is in continuation to our earlier intimation dated April 22, 2022, with respect to the ensuing meeting of the Board of Directors of the Company, scheduled on April 29, 2022. In terms of Regulation 29 of the SEBI Listing Regulations, we wish to inform that the Board of Directors, at its meeting scheduled to be held on Friday, April 29, 2022, shall also consider and recommend Dividend, if any, for the financial year 2021-22. With reference to the earlier intimation dated April 22, 2022, with respect to the ensuing meeting of the Board of Directors of the Company, scheduled on April 29, 2022. Solara Active Pharma Sciences Ltd has now informed BSE that the Board of Directors, at its meeting scheduled to be held on April 29, 2022, shall also consider and recommend Dividend, if any, for the financial year 2021-22. (As Per BSE Announcement Dated on 26.04.2022) Audited financial results (standalone and consolidated) of the Company for the quarter andYear ended March 31, 2022 pursuant to Regulation 33 of SEBI (Listing Obligations andDisclosure Requirements) Regulation, 2015. A copy of the audited financial results(standalone and consolidated) for the quarter and year ended March 31, 2022 along with the Auditors report for the said period and press release on the same is attached Intimation for withdrawal of the Composite Scheme of Amalgamation We wish to inform you that Mr. Rajender Rao Juvvadi has resigned from the position of Managing director and CEO and directorship of the company with effect from April 28, 2022. Kindly take the same on record We wish to inform that Mr. Jitesh Devendra has been appointed as Managing Director of the company with effect from April 29, 2022. (As Per BSE Announcement Dated on 29.04.2022)
Board Meeting - 09-Mar-2022 - -
We wish to inform you that the Board of Directors of the Company has taken on record/approved the Resignation of Mr. Subhash Anand as Executive director and Chief Financial Officer and Appointment of Mr. S. Hariharan as Chief Financial Officer of the company at its meeting held on March 9, 2022. We wish to inform that meeting of Board of Directors of Solara Active Pharma Sciences Limited held today (i.e., March 9, 2022), the Board has approved the allotment of 30,000 equity shares against the Solara Employee Stock Option Plan 2018.
Board Meeting - 31-Jan-2022 - -
Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2022 inter alia to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Wednesday February 9 2022 to inter alia consider and approve the unaudited financial results (standalone and consolidated) of the Company for the quarter and nine months period ended December 31 2021 amongst other matters. Financial results for the period ended december 31st, 2021 We wish to inform that meeting of Board of Directors of Solara Active Pharma Sciences Limited (Company) held today (i.e., February 9, 2022), the Board has approved the allotment of 20,000 equity shares against the Solara Employee Stock Option Plan 2018. (As per BSE Announcement Dated on 09/02/2022) Please find enclosed copies of the newspaper advertisement titled Consolidated unaudited financial results for quarter and nine months ended December 31, 2021. The advertisements appeared in Business Standard and Lokmat (Marathi version). (As Per BSE Announcement Dated 14.02.2022)
Board Meeting - 26-Nov-2021 - -
This is in continuation to our letter dated l l th November 202 l intimating the approval of the Board of Directors of the Company (the Board) to the Composite Scheme of Amalgamation (Merger by Absorption) cum Demerger and Arrangement amongst Hydra Active Pharma Sciences Private Limited (Hydra or the Amalgamating Company l or Transferor Company l ) and Aurore Life Sciences Private Limited (Aurore Life Sciences or the Amalgamated Company l or Transferee Company l or Demerged Company) and Empyrean Lifesciences Private Limited (Empyrean or the Amalgamating Company 2 or Transferor Company 2) and Solara Active Pharma Sciences Limited (Solara or the Company or Amalgamated Company 2 or Transfelt:t: Cumpauy 2 or Resulting Company) (Hydra Empyrean Solara and Aurore Life Sciences are collectively referred to as Companies) and their respective shareholders (hereinafter referred to as the Scheme).
Board Meeting - 03-Nov-2021 - -
Quarterly Results The Board has approved the allotment of 16,500 equity shares against the Solara Employee Stock Option Plan 2018. Consequent to the said allotment, the paid-up share capital of the Company will increase from Rs. 35,92,97,670 consisting of 3,59,29,767 equity shares of Rs. 10 each to Rs. 35,94,62,670 consisting of 3,59,46,267 equity shares of Rs. 10 each. We hereby enclose the notification pursuant to Regulation 10(c) of SEBI (Share Based Employee Benefits) Regulations, 2014 and Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as Annexure A. (As Per BSE Announcement Dated 11.11.2021)
Board Meeting - 25-Aug-2021 - -
The outcome of the meeting of the Board of Directors of Solara Active Pharma Sciences Limited (Company) held on 25th August 2021 - Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, as amended from time to time.
Board Meeting - 27-Jul-2021 - -
Solara Active Pharma Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2021 ,inter alia, to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Wednesday, August 4, 2021 to inter alia consider and approve, the unaudited financial results (standalone and consolidated) of the Company for the quarter ended June 30, 2021, amongst other matters. In accordance with the Companys Code of Conduct to regulate, monitor and report trading by insiders, adopted by the Board pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the securities of the Company is closed for the designated persons from July 1, 2021 till 48 hours after the announcement of financial results i.e. upto August 6, 2021 (both days inclusive). Please refer our letter dated July 28, 2021 under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, in continuation we wish to inform that at the meeting of Board of Directors held today (August 4, 2021) the Directors has inter-alia approved Unaudited financial results (standalone and consolidated) of the Company for the quarter ended June 30, 2021. The outcome of Board meeting dated August 4, 2021 - Change in Directorate. (As Per BSE Announcement Dated on 04.08.2021)
Open ZERO Brokerage Demat Account Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity